Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1987 1
1989 2
1990 1
1994 1
1995 1
1997 2
2001 1
2002 3
2003 1
2004 2
2005 3
2006 1
2007 7
2008 3
2009 5
2010 1
2011 1
2012 2
2013 3
2014 5
2015 5
2016 7
2017 8
2018 8
2019 9
2020 10
2021 12
2022 8
2023 12
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Cervical Squamous Cell Carcinoma"
Page 1
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Ferris RL, et al. N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8. N Engl J Med. 2016. PMID: 27718784 Free PMC article. Clinical Trial.
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. ...CONCLUSIONS: Among patients with platinum-refractory, recur …
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum ch …
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline.
Yilmaz E, Ismaila N, Bauman JE, Dabney R, Gan G, Jordan R, Kaufman M, Kirtane K, McBride SM, Old MO, Rooper L, Saba NF, Sheth S, Subramaniam RM, Wise-Draper TM, Wong D, Mell LK. Yilmaz E, et al. J Clin Oncol. 2023 Feb 10;41(5):1132-1146. doi: 10.1200/JCO.22.02328. Epub 2022 Dec 15. J Clin Oncol. 2023. PMID: 36521102 Review.
PURPOSE: To provide evidence-based recommendations for practicing physicians and other health care providers on immunotherapy and biomarker testing for head and neck cancers. METHODS: ASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, …
PURPOSE: To provide evidence-based recommendations for practicing physicians and other health care providers on immunotherapy and biomarker …
B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
Gavrielatou N, Fortis E, Spathis A, Anastasiou M, Economopoulou P, Foukas GRP, Lelegiannis IM, Rusakiewicz S, Vathiotis I, Aung TN, Tissot S, Kastrinou A, Kotsantis I, Vagia EM, Panayiotides I, Rimm DL, Coukos G, Homicsko K, Foukas P, Psyrri A. Gavrielatou N, et al. Ann Oncol. 2024 Apr;35(4):340-350. doi: 10.1016/j.annonc.2023.12.011. Epub 2023 Dec 28. Ann Oncol. 2024. PMID: 38159908 Free article. Clinical Trial.
BACKGROUND: Programmed cell death protein 1 (PD-1) axis blockade has become the mainstay in the treatment of recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC). ...This result was validated by GSEA, as stromal enrichment with …
BACKGROUND: Programmed cell death protein 1 (PD-1) axis blockade has become the mainstay in the treatment of recurrent and/or metasta …
Immunotherapy for squamous cell carcinoma of the head and neck.
Yokota T, Homma A, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, Ogawa T, Saito Y, Sano D, Kodaira T, Motegi A, Yasuda K, Takahashi S, Tanaka K, Onoe T, Okano S, Imamura Y, Ariizumi Y, Hayashi R; Japan Clinical Oncology Group (JCOG) Head and Neck Cancer Study Group. Yokota T, et al. Jpn J Clin Oncol. 2020 Sep 28;50(10):1089-1096. doi: 10.1093/jjco/hyaa139. Jpn J Clin Oncol. 2020. PMID: 32776100 Review.
Squamous cell carcinoma of the head and neck is characterized by an immunosuppressive environment and evades immune responses through multiple resistance mechanisms. ...CheckMate141 and KEYNOTE-048 were practice-changing randomized phase 3 trials for p …
Squamous cell carcinoma of the head and neck is characterized by an immunosuppressive environment and evades imm …
Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Okada T, Matsuki T, Fushimi C, Okamoto I, Sato H, Kondo T, Tokashiki K, Ito T, Masubuchi T, Tada Y, Miura K, Hanyu K, Omura GO, Takahashi H, Yamashita T, Oridate N, Tsukahara K. Okada T, et al. Anticancer Res. 2022 Oct;42(10):4907-4912. doi: 10.21873/anticanres.15996. Anticancer Res. 2022. PMID: 36192003
BACKGROUND/AIM: Nivolumab has antitumor efficacy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who relapse within 6 months after platinum-based therapy; however, the efficacy of nivolumab for platinum-sensitive …
BACKGROUND/AIM: Nivolumab has antitumor efficacy in patients with recurrent/metastatic head and neck squamous cell c …
Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinoma.
Marret G, Borcoman E, Le Tourneau C. Marret G, et al. Curr Opin Oncol. 2023 May 1;35(3):158-165. doi: 10.1097/CCO.0000000000000940. Epub 2023 Mar 14. Curr Opin Oncol. 2023. PMID: 36966501 Review.
PURPOSE OF REVIEW: We review the window-of-opportunity clinical trials that have been reported in head and neck squamous cell carcinoma (HNSCC), and discuss their challenges. RECENT FINDINGS: Limited treatment options exist in HNSCC. ...The only valida …
PURPOSE OF REVIEW: We review the window-of-opportunity clinical trials that have been reported in head and neck squamous ce …
Role of Immunotherapy in Head and Neck Cancer.
Ling DC, Bakkenist CJ, Ferris RL, Clump DA. Ling DC, et al. Semin Radiat Oncol. 2018 Jan;28(1):12-16. doi: 10.1016/j.semradonc.2017.08.009. Semin Radiat Oncol. 2018. PMID: 29173750 Review.
Immune system dysfunction plays a role in both the development and progression of head and neck squamous cell carcinoma (HNSCC), highlighting the potential role for immunotherapy to improve outcomes in this disease. ...Finally, early phase I studies ar …
Immune system dysfunction plays a role in both the development and progression of head and neck squamous cell carcin …
Distant Intramuscular Metastases of Head and Neck Squamous Cell Carcinoma.
Hsu I, Yen CW, Huang KF, Lin YS. Hsu I, et al. Ann Plast Surg. 2020 Jan;84(1S Suppl 1):S11-S16. doi: 10.1097/SAP.0000000000002175. Ann Plast Surg. 2020. PMID: 31833883
OBJECTIVES: Metastasis of head and neck squamous cell carcinoma (HNSCC) usually occurs regionally in the neck lymph nodes, but also more infrequently at distant organs (eg, the lungs, bone, and liver). ...Radiotherapy is established as a first-l …
OBJECTIVES: Metastasis of head and neck squamous cell carcinoma (HNSCC) usually occurs regionally in the neck …
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Serafini MS, Cavalieri S, Licitra L, Pistore F, Lenoci D, Canevari S, Airoldi M, Cossu Rocca M, Strojan P, Kuhar CG, Merlano M, Perrone F, Vingiani A, Denaro N, Perri F, Argiris A, Gurizzan C, Ghi MG, Cassano A, Allegrini G, Bossi P, De Cecco L. Serafini MS, et al. J Immunother Cancer. 2024 Jan 30;12(1):e007823. doi: 10.1136/jitc-2023-007823. J Immunother Cancer. 2024. PMID: 38290766 Free PMC article. Clinical Trial.
BACKGROUND: Immune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit in clinical trials is variable and he …
BACKGROUND: Immune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head a …
Five-year follow-up of nivolumab treatment in Japanese patients with esophageal squamous-cell carcinoma (ATTRACTION-1/ONO-4538-07).
Satoh T, Kato K, Ura T, Hamamoto Y, Kojima T, Tsushima T, Hironaka S, Hara H, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Doki Y, Matsumura Y, Kitagawa Y. Satoh T, et al. Esophagus. 2021 Oct;18(4):835-843. doi: 10.1007/s10388-021-00850-0. Epub 2021 May 16. Esophagus. 2021. PMID: 33993388 Free PMC article. Clinical Trial.
METHODS: We enrolled patients with esophageal cancer that was refractory or intolerant to a standard chemotherapy. Then, nivolumab (3 mg/kg) was administered every 2 weeks. ...RESULTS: Nivolumab was administered to 65 patients with esophageal squamous-cell …
METHODS: We enrolled patients with esophageal cancer that was refractory or intolerant to a standard chemotherapy. Then, nivolumab (3 …
114 results